Amgen subpoenaed on anemia treatments
Amgen Inc., the world’s largest biotechnology company, said Friday that it received a second subpoena from the U.S. attorney’s office in Washington state in connection with the company’s anemia drugs.
Amgen received the “supplemental” subpoena July 18 for documents regarding “the sales and marketing of our products, and our collection and dissemination of information” on the drugs’ efficacy and safety, the Thousand Oaks company said in a filing with the Securities and Exchange Commission.
The House Committee on Energy and Commerce, led by Rep. John D. Dingell (D-Mich.), said March 31 that it was asking Amgen for documents on its print and television advertising.
Last year, Amgen got subpoenas seeking information about its products from the U.S. attorney’s office in Seattle and from the U.S. attorney’s office for the Eastern District of New York, the company said in a Nov. 12 filing.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
